Immuneering Co. (NASDAQ:IMRX) Receives $13.50 Average PT from Analysts

Shares of Immuneering Co. (NASDAQ:IMRX) have earned an average rating of “Moderate Buy” from the eight research firms that are presently covering the company, Marketbeat.com reports. Four research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $13.50.

Several equities analysts recently weighed in on the stock. Chardan Capital cut their price target on shares of Immuneering from $21.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, March 15th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 price target on shares of Immuneering in a report on Friday. Guggenheim restated a “neutral” rating on shares of Immuneering in a research report on Thursday, March 14th. Mizuho lowered their price objective on Immuneering from $20.00 to $8.00 and set a “buy” rating on the stock in a research report on Tuesday, April 2nd. Finally, Jefferies Financial Group restated a “hold” rating and issued a $3.00 price objective (down previously from $16.00) on shares of Immuneering in a research report on Friday, March 15th.

Insider Activity

In other Immuneering news, Director Ann E. Berman bought 57,965 shares of the firm’s stock in a transaction dated Monday, March 18th. The shares were purchased at an average price of $2.13 per share, for a total transaction of $123,465.45. Following the transaction, the director now directly owns 67,465 shares of the company’s stock, valued at approximately $143,700.45. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Peter Feinberg acquired 25,000 shares of Immuneering stock in a transaction that occurred on Friday, March 22nd. The stock was purchased at an average cost of $2.55 per share, with a total value of $63,750.00. Following the purchase, the director now owns 111,766 shares in the company, valued at $285,003.30. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Ann E. Berman acquired 57,965 shares of Immuneering stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average cost of $2.13 per share, with a total value of $123,465.45. Following the completion of the purchase, the director now owns 67,465 shares in the company, valued at approximately $143,700.45. The disclosure for this purchase can be found here. Insiders have acquired 111,790 shares of company stock worth $266,645 in the last quarter. Corporate insiders own 23.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. UBS Group AG acquired a new stake in shares of Immuneering in the 1st quarter worth $26,000. Tower Research Capital LLC TRC increased its stake in shares of Immuneering by 296.1% in the 3rd quarter. Tower Research Capital LLC TRC now owns 3,248 shares of the company’s stock worth $25,000 after acquiring an additional 2,428 shares during the last quarter. Citigroup Inc. increased its stake in shares of Immuneering by 2,078.7% in the 2nd quarter. Citigroup Inc. now owns 6,536 shares of the company’s stock worth $66,000 after acquiring an additional 6,236 shares during the last quarter. California State Teachers Retirement System acquired a new stake in shares of Immuneering in the 2nd quarter worth $68,000. Finally, Barclays PLC increased its stake in shares of Immuneering by 56.1% in the 2nd quarter. Barclays PLC now owns 8,144 shares of the company’s stock worth $82,000 after acquiring an additional 2,927 shares during the last quarter. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Stock Up 1.0 %

IMRX opened at $2.10 on Tuesday. Immuneering has a 52-week low of $1.90 and a 52-week high of $14.29. The company has a market cap of $61.49 million, a P/E ratio of -1.11 and a beta of -0.89. The firm’s 50-day moving average price is $4.60 and its 200-day moving average price is $5.91.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings results on Friday, March 1st. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.06). On average, research analysts anticipate that Immuneering will post -1.89 EPS for the current fiscal year.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.